Chiwoo Oh: AS01B Adjuvant and Long-Term Immune Reprogramming After Shingrix Vaccination
Chiwoo Oh, Postdoctoral Research Fellow at Harvard Medical School, shared a post on LinkedIn about recent article by Fabiana Corsi-Zuelli et al, published in Nature Medicine, adding:
“The AS01B adjuvant (MPL plus QS 21) in Shingrix initially induces strong innate immune activation but subsequently causes long term reprogramming of the chromatin and transcriptional state of monocytes, reducing inflammatory cytokine responses such as IL6 upon subsequent TLR stimulation.
This may, in turn, decrease chronic vascular and atherosclerosis-associated inflammation, potentially lowering the risk of cardiovascular events.”
Title: Recombinant shingles vaccination and the risk of cardiovascular events
Authors: Fabiana Corsi-Zuelli, Fang Li, Rachel Upthegrove, John A. Todd, Betty Raman, Paul J. Harrison, Maxime Taquet
Stay updated on all scientific advances with Hemostasis Today.
-
Oct 19, 2026, 19:44Where You Live Should not Determine Whether You Receive Care – World Federation of Hemophilia
-
Oct 19, 2026, 19:42Belen Bianco: Prevention, Early Suspicion and an Interdisciplinary Approach Save Lives
-
Oct 19, 2026, 19:40Christina Chrysohoou: Catheter-Based LAAC vs OAC for Stroke Prevention in Atrial Fibrillation
-
Oct 19, 2026, 19:38Matthew Flick: A Two-Day Research Meeting on Fibrinogen, Hemostasis and Thrombosis
-
Oct 19, 2026, 19:37Hayat Saeed: Excited to Share Our Publication on the FGL1–Hepcidin Axis in Iron Homeostasis and Disease
-
Oct 19, 2026, 19:08IPAW 2026 Comes to a Close, but the Work Continues – PPTA
-
Oct 19, 2026, 17:44Paul Riley: Moderating a Webinar on Anticoagulation Monitoring
-
Oct 19, 2026, 16:36Christopher Pittman: Blood Clot Prevention Cannot End at Hospital Discharge
-
Oct 19, 2026, 16:13Javier M. Floren: When Immune Cells Move With Their Environment